IL13RA2 and central nervous system cancer: Further, encouraging results were published in an adult patient treated this time with autologous IL13Rα2 CAR T as part of a clinical trial investigating the efficacy of IL13Rα2 CAR T cells, open to patients over the age of 12 with recurrent or refractory glioma (NCT02208362) (6).